BridgeBio Oncology Therapeutics, Inc. (BBOT)
Nasdaq: BBOT · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2023
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 5, 2026 | Mar 11, 2025 | · |
| For lenders | |||
| Interest and dividend income | 11,343,000 | 6,377,000 | · |
| Interest and investment income | · | 8,449,291 | · |
| Research and development | 121,199,000 | 73,107,000 | · |
| General and administrative | 24,620,000 | 7,756,000r | 41,692 |
| Total operating expenses | 145,819,000 | 80,863,000 | · |
| Operating income | -145,819,000 | -80,863,000r | -41,692 |
| Other income (expense), net | -35,000 | 0 | · |
| Total non-operating income (expense) | 11,775,000 | 6,588,000r | · |
| Income tax expense | 0 | 0 | · |
| Net income | -134,044,000 | -74,275,000r | -41,692 |
| Earnings per share, basic | -4.30 | -5,756.41 | · |
| Earnings per share, diluted | -4.30 | -5,756.41 | · |
| Weighted average shares, basic | 31,144,775 | 12,903 | · |
| Weighted average shares, diluted | 31,144,775 | 12,903 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Interest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding